Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib Monotherapy vs Talazoparib Plus Temozolomide in Relapsed Ovarian Cancer
NCT02836028Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of talazoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Pfizer. Planned start Oct 2016; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02836028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836028.